---
$id: https://graph.org.ai/products/commodity/51131738
$type: Product
source: UNSPSC
code: "51131738"
title: "Rocepafant"
class: "51131700"
classTitle: "Thrombolytic drugs and platelet aggregation inhibitors"
family: "51130000"
familyTitle: "Hematolic drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Rocepafant

**UNSPSC Code**: 51131738
**Class**: [Thrombolytic drugs and platelet aggregation inhibitors](Thrombolytic drugs and platelet aggregation inhibitors.mdx)
**Family**: [Hematolic drugs](../Hematolic drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an antiplatelet agent with the molecular formula C26H23ClN6OS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4KGX1STY2N, chemically known as 6-(o-chlorophenyl)-7,10-dihydro-1-methylthio-4h-pyrido(4,3:4,5)thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine-9(8h)-carboxy-p-anisidide but generally known as rocepafant, which bears US NIH Compound Identifier 3033963. European Medicines Agency schedules Rocepafant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10350MIG. The term ROCEPAFANT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). ROCEPAFANT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rocepafant under HS 29349990 and SITC 51579. As of Q4 2014, ROCEPAFANT remains the US FDA Preferred Term for this commodity. Rocepafant bears US NLM identifiers UMLS ID C2347968 and NCI Concept Code C73133. SMILES: CLC1C(C2=NCC3N(C4SC5C(CCN(C5)C(=S)NC5CCC(OC)CC5)C24)C(NN3)C)CCCC1.

